Meza-Junco J, Montaño-Loza A, Aguayo-González Á

Language: Spanish
References: 42
Page: 56-70
PDF size: 150.62 Kb.

ABSTRACT

Cancer is a group of diseases characterized by an autonomous proliferation of neoplastic cells which have a number of alterations, including mutations and genetic instability. Cellular functions are controlled by proteins, and because these proteins are encoded by DNA organized into genes, molecular studies have shown that cancer is a paradigm of acquired genetic disease. The process of protein production involves a cascade of several different steps, each with its attendant enzymes, which are also encoded by DNA and regulated by other proteins. Most steps in the process can be affected, eventually leading to an alteration in the amount or structure of proteins, which in turn affects cellular function. However, whereas cellular function may be altered by disturbance of one gene, malignant transformation is thought to require two or more abnormalities occurring in the same cell. Although there are mechanisms responsible for DNA maintenance and repair, the basic structure of DNA and the order of the nucleotide bases can be mutated. These mutations can be inherited or can occur sporadically, and can be present in all cells or only in the tumor cells. At the nucleotide level, these mutations can be substitutions, additions or deletions. Several of the oncogenes discussed below, including the p53, c-fms, and Ras genes, can be activated by point mutations that lead to aminoacid substitution in critical portions of the protein. This article examines the current concepts relating to cellular mechanism that underlie the molecular alterations that characterize the development of cancer.

REFERENCES

1. Willingham AT, Deveraux QL, Hampton GM, et al. RNAi and HTS: exploring cancer by systematic loss-of-function. Oncogene 2004; 23: 8392-400.

2. Valko M, Izakovic M, Mazur M, et al. Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem 2004; 266: 37-56.

3. Dey P. Aneuploidy and malignancy: an unsolved equation. J Clin Pathol 2004; 57: 1245-9.

4. Stehelin D. The transforming gene of avian tumor viruses. Pathol Biol 1976; 24: 513-15.

5. Hethcote HW, Knudson AG Jr. Model for the incidence of embryonal cancers: application to retinoblastoma. Proc Natl Acad Sci USA 1978; 75: 2453-7.

6. Gillison ML. Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol 2004; 31: 744-54.

7. Shah KV. Simian virus 40 and human disease. J Infect Dis 2004; 190: 2061-4.

8. Williams JF, Zhang Y, Williams MA, et al. E1A-based determinants of oncogenicity in human adenovirus groups A and C. Curr Top Microbiol Immunol 2004; 273: 245-88.

9. Akashi M, Koeffler HP. Li-Fraumeni syndrome and the role of the p53 tumor suppressor gene in cancer susceptibility. Clin Obstet Gynecol 1998; 41: 172-99.

10. Vousden KH, Prives C. P53 and prognosis: new insights and further complexity. Cell 2005; 120: 7-10.

11. Wei MC. Bcl-2-related genes in lymphoid neoplasia. Int J Hematol 2004; 80: 205-9.

12. Akgul C, Moulding DA, Edwards SW. Alternative splicing of Bcl-2-related genes: functional consequences and potential therapeutic applications. Cell Mol Life Sci 2004; 61: 2189-99.

13. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994; 266: 1821-8.

14. Wasch R, Engelbert D. Anaphase-promoting complex-dependent proteolysis of cell cycle regulators and genomic instability of cancer cells. Oncogene 2005; 24: 1-10.

15. Marston AL, Amon A. Meiosis: cell-cycle controls shuffle and deal. Nat Rev Mol Cell Biol 2004; 5: 983-97.

16. Porter LA, Donoghue DJ. Cyclin B1 and CDK1: nuclear localization and upstream regulators. Prog Cell Cycle Res 2003; 5: 335-47.

17. Sage J. Cyclin C makes an entry into the cell cycle. Dev Cell 2004; 6: 607-8.

18. Gladden AB, Diehl JA. Cell cycle progression without cyclin E/CDK2: breaking down the walls of dogma. Cancer Cell 2003; 4: 160-2.

19. Yasmeen A, Berdel WE, Serve H, et al. E- and A-type cyclins as markers for cancer diagnosis and prognosis. Expert Rev Mol Diagn 2003; 3: 617-33.

20. Vadlamudi RK, Kumar R. p21-activated kinase 1: an emerging therapeutic target. Cancer Treat Res 2004; 119: 77-88.

21. Pagano M. Control of DNA synthesis and mitosis by the Skp2-p27-Cdk1/2 axis. Mol Cell 2004; 14: 414-6.

22. Satyanarayana A, Rudolph KL. p16 and ARF: activation of teenage proteins in old age. J Clin Invest 2004; 114: 1237-40.

23. Swanton C. Cell-cycle targeted therapies. Lancet 2004; 5: 27-36.

24. Murray AW. Recycling the cell cycle: cyclins revisited. Cell 2004; 116: 221-34.

25. Jones AV, Cross NC. Oncogenic derivatives of platelet-derived growth factor receptors. Cell Mol Life Sci 2004; 61: 2912-23.

26. Pomerantz RG, Grandis JR. The epidermal growth factor receptor signaling network in head and neck carcinogenesis and implications for targeted therapy. Semin Oncol 2004; 31: 734-43.

27. Gibson SB. Epidermal growth factor and trail interactions in epithelial-derived cells. Vitam Horm 2004; 67: 207-27.

28. Chen CH, Poucher SM, Lu J, Henry PD. Fibroblast growth factor 2: from laboratory evidence to clinical application. Curr Vasc Pharmacol 2004; 2: 33-43.

29. Funakoshi H, Nakamura T. Hepatocyte growth factor: from diagnosis to clinical applications. Clin Chim Acta 2003; 327: 1-23.

30. Jenkins PJ, Bustin SA. Evidence for a link between IGF-I and cancer. Eur J Endocrinol 2004; 151(Suppl 1): 17-22.

31. Mocchetti I, Bachis A. Brain-derived neurotrophic factor activation of TrkB protects neurons from HIV-1/gp120-induced cell death. Crit Rev Neurobiol 2004; 16: 51-7.

32. Heldin CH. Platelet-derived growth factor. An introduction. Cytokine Growth Factor Rev 2004; 15: 195-6.

33. McColl BK, Stacker SA, Achen MG. Molecular regulation of the VEGF family-inducers of angiogenesis and lymphangiogenesis. APMIS 2004; 112: 463-80.

34. Chiarugi V, Ruggiero M, Magnelli L. Molecular polarity in endothelialcells and tumor-induced angiogenesis. Oncol Res 2000; 12: 1-4.

35. Sauvageau G, Iscove NN, Humphries RK. In vitro and in vivo expansion of hematopoietic stem cells. Oncogene 2004; 23: 7223-32.

36. Lukas J, Parry D, Aagaard L, et al. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumor suppresor p16. Nature 1995; 375: 503-6.

37. Lane D. Curing Cancer with p53. N Engl J Med 2004; 350: 25-6.

38. Crighton D, Ryan KM. Splicing DNA-damage responses to tumour cell death. Biochim Biophys Acta 2004; 1705: 3-15.

39. Dass CR. Tumour angiogenesis, vascular biology and enhanced drug delivery. J Drug Target 2004; 12: 245-55.

40. Sheen IS, Jeng KS, Jeng WJ, et al. Fumagillin treatment of hepatocellular carcinoma in rats: An in vivo study of antiangiogenesis. World J Gastroenterol 2005; 11: 771-7.

41. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005; 352: 476-87.

42. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.